G. STUDY DESIGN: It is assumed that the new regimen will not be of further interest in t(4;14) positive myeloma patients if the TTP from the time of starting induction therapy is less than 21 months. Each patient will be followed every month until disease progression and then after every 6 moths up to 5 years for survival. An interim analysis will also be performed after 12 patients have completed the post-induction therapy with cyclophosphamide + bortezomib + prednisone (CyBorP).